These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26920612)

  • 1. [Long-term results in neovascular age-related macular degeneration : Changes in visual acuity and geographic atrophy during long-standing anti-VEGF therapy].
    Thalgott V; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Aug; 113(8):668-74. PubMed ID: 26920612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
    Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
    Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
    Boulanger-Scemama E; Sayag D; Ha Chau Tran T; Quaranta-El Maftouhi M; Rumen F; Creuzot-Garcher C; Blanco Garavito R; Jung C; Souied E
    J Fr Ophtalmol; 2016 Oct; 39(8):668-674. PubMed ID: 27609025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
    Berg K; Roald AB; Navaratnam J; Bragadóttir R
    Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration].
    Duval MV; Rougier MB; Delyfer MN; Combillet F; Korobelnik JF
    J Fr Ophtalmol; 2017 Apr; 40(4):270-278. PubMed ID: 28341388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
    Grunwald JE; Pistilli M; Ying GS; Maguire MG; Daniel E; Martin DF;
    Ophthalmology; 2015 Apr; 122(4):809-16. PubMed ID: 25542520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Sagiv O; Zloto O; Moroz I; Moisseiev J
    Ophthalmologica; 2017; 238(4):217-225. PubMed ID: 28926846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Kung FF; Starr MR; Bui YT; Mejia CA; Bakri SJ
    Ophthalmol Retina; 2020 Nov; 4(11):1047-1053. PubMed ID: 32439455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.